0A64 Stock Overview
A development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Oragenics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$7.45 |
| 52 Week Low | US$0.26 |
| Beta | 0.45 |
| 1 Month Change | 45.52% |
| 3 Month Change | -7.58% |
| 1 Year Change | -92.43% |
| 3 Year Change | -98.57% |
| 5 Year Change | n/a |
| Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A64 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 19.7% | -5.0% | -1.9% |
| 1Y | -92.4% | -24.4% | 2.6% |
Return vs Industry: 0A64 underperformed the UK Biotechs industry which returned -24.4% over the past year.
Return vs Market: 0A64 underperformed the UK Market which returned 2.6% over the past year.
Price Volatility
| 0A64 volatility | |
|---|---|
| 0A64 Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A64's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0A64's weekly volatility has decreased from 30% to 15% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 5 | Janet Huffman | www.oragenics.com |
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics.
Oragenics, Inc. Fundamentals Summary
| 0A64 fundamental statistics | |
|---|---|
| Market cap | US$4.62m |
| Earnings (TTM) | -US$19.97m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs 0A64 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A64 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$13.49m |
| Gross Profit | -US$13.49m |
| Other Expenses | US$6.48m |
| Earnings | -US$19.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 16.9% |
How did 0A64 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:31 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oragenics, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Theodore O'Neill | Ascendiant Capital Markets LLC |
| Keith Markey | Griffin Securities |